Issue 4, 2019, Issue in Progress
From the journal:

RSC Advances

DNA–affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy†

Chao Zhang,a   HongLei Zhang, ORCID logo *a   MengNan Han,a   XueLi Yang,a   ChaoHong Pei,a   ZhiDong Xu,ac   Jie Du,*a   Wei Li ORCID logo *a  and  Shengxi Chen ORCID logo b  

* Corresponding authors

a Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, College of Chemistry and Environmental Science, Hebei University, Baoding 071002, China
E-mail: liweihebeilab@163.com

b Center for BioEnergetics, Biodesign Institute, Arizona State University, Tempe 85287, USA

c Shijiazhuang Vince Pharmatech Co. Ltd., China

Abstract

Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron–affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57% at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9%, 33.3 μM).

Graphical abstract: DNA–affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy

About
Cited by
Related
Download options Please wait...

Supplementary files

Article information

DOI
https://doi.org/10.1039/C8RA08735K
Article type
Paper
Submitted
22 Oct 2018
Accepted
06 Jan 2019
First published
15 Jan 2019
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2019,9, 1982-1989

Permissions

Request permissions

DNA–affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy

C. Zhang, H. Zhang, M. Han, X. Yang, C. Pei, Z. Xu, J. Du, W. Li and S. Chen, RSC Adv., 2019, 9, 1982 DOI: 10.1039/C8RA08735K

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements